Another study demonstrated higher and lower expression of ERα and ERβ, respectively, in resected NSCLC specimens from the patients, serving as a poor prognosis in NSCLC patients, and the absence of ERβ might be used as a plausible marker to identify individuals who are at higher risk in their treatment [105]. The gene discussed is ESR1; the disease is non-small cell lung carcinoma.